Comparative Effectiveness and Safety of FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: A GRADE-assessed Systematic Review and Meta-analysis.

oxaliplatin - Generic mfg.

Erbitux (cetuximab) - Eli Lilly

5-fluorouracil - Generic mfg.

irinotecan - Generic mfg.

Avastin (bevacizumab) - Roche

leucovorin calcium - Generic mfg.

Comparative Effectiveness and Safety of FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: A GRADE-assessed Systematic Review and Meta-analysis. (PubMed, J Gastrointest Cancer) - Oct 1, 2026 - "FOLFOXIRI-cetuximab did not improve PFS, OS, or response rates in patients with mCRC compared with the bevacizumab combination; however, it was associated with significantly higher rates of hypomagnesemia and acneiform rash."
Clinical • HEOR • Journal • Retrospective data • Review • Alopecia • Colorectal Cancer • Dental Disorders • Hematological Disorders • Immunology • Oncology • Solid Tumor • Stomatitis

http://www.ncbi.nlm.nih.gov/pubmed/42814239

Ahmed Raza; Faiza Fatima; Mahnoor Fatima; Maria Qadri; Muhammad Ansab; Muhammad Saffi Ullah; Navkirat Kahlon; Zaheer Qureshi; Zain Sadiq

Oct 1, 2026